
==== Front
BMC Immunol
BMC Immunol
BMC Immunology
1471-2172
BioMed Central London

39271997
651
10.1186/s12865-024-00651-x
Research
β-glucan combined with Envafolimab and Endostar as immune rechallenge for metastatic non-small cell lung cancer
Geng Qian 12
Lu Yingying 2
Li Dongqing 12
Qin Lanqun 12
Qi Chunjian 13
Pu Xiaolin 12
Zhuang Yi 4
Zhu Yajun 5
Zha Quanbin 5
Wang Ge 12
Jiang Hua czeyjh@njmu.edu.cn

12
1 https://ror.org/059gcgy73 grid.89957.3a 0000 0000 9255 8984 Changzhou Medical Center, Nanjing Medical University, Changzhou, 213003 China
2 https://ror.org/04bkhy554 grid.430455.3 Department of Oncology, The Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University, Changzhou, 213003 China
3 https://ror.org/04bkhy554 grid.430455.3 Medical Research Center, The Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University, Changzhou, 213003 China
4 Department of Oncology, Changzhou Wujin Hospital of TCM, Changzhou, 213003 China
5 https://ror.org/03jc41j30 grid.440785.a 0000 0001 0743 511X Department of Oncology, Jintan Hospital Affiliated to Jiangsu University, Changzhou, Jiangsu 213200 China
14 9 2024
14 9 2024
2024
25 6020 7 2024
5 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

Immune checkpoint inhibitor rechallenge has emerged as a prominent study area in non-small cell lung cancer (NSCLC). β-glucan was reported to reverse resistance to anti-PD-1/PD-L1 inhibitors by regulating the tumor microenvironment. In this self-initiated clinical trial (ChiCTR2100054796), NSCLC participants who have previously failed anti-PD-1 therapy received β-glucan (500 mg, bid, d1-21), Envafolimab (300 mg, d1) and Endostar (210 mg, civ72h) every 3 weeks until disease progression or unacceptable toxicity. The clinical efficacy and adverse events were observed, while serum samples were collected for proteomic analysis.

Results

Twenty Three patients were enrolled from January 2022 to March 2023 (median age, 65 years; male, n = 18 [78.3%]; squamous NSCLC, n = 9 [39.1%]; mutant type, n = 13 [56.5%]). The overall response rate (ORR) was 21.7% and disease control rate (DCR) was 73.9%. Median progression-free survival (mPFS) and median overall survival (mOS) was 4.3 months [95% CI: 2.0–6.6] and 9.8 months [95% CI: 7.2–12.4], respectively. The mPFS between PD-L1 positive and negative subgroup has significant difference (6.3 months vs. 2.3 months, p = 0.002). Treatment-related adverse events (TRAEs) occurred in 52.2% of patients. The most common TRAEs were hypothyroidism (26.1%) and fatigue (26.1%). 2 (8.7%) grade 3 adverse events were reported. No adverse reaction related deaths have been observed. Proteomic analysis revealed that the levels of CASP-8, ARG1, MMP12, CD28 and CXCL5 correlated with resistance to the treatment while the levels of CD40-L and EGF related to the favorable response.

Conclusion

β-glucan combined with Envafolimab and Endostar has considerable efficacy and safety for immune rechallenge in metastatic NSCLC patients who failed of anti-PD-1 treatment previously, especially for PD-L1 positive patients.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12865-024-00651-x.

Keywords

β-glucan
Envafolimab
Immune checkpoint inhibitors
Rechallenge
Non-small cell lung cancer
issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer [1]. With the development of immunotherapy, immune checkpoint inhibitors (ICIs) typified by anti-programmed cell death-1 (PD-1) /anti-programmed cell death ligand-1 (PD-L1) inhibitors have become the main treatment option for advanced NSCLC due to their sustaining anti-tumor efficacy and tolerable safety profile [2]. However, ICIs only benefits a small number of patients and a significant proportion of patients could develop primary or acquired drug resistance to ICIs [3], which has become an important issue that cannot be ignored. At present, there is a lack of consistent guidelines or consensus on the evaluation criteria for immunotherapy resistance and the choice of intensive treatment after immune resistance. To solve this dilemma, multiple combination therapies have been explored, including ICIs combined with chemotherapy or targeted drugs, dual immunotherapy, systemic immunotherapy in conjunction with local radiotherapy, exploration of other immune checkpoints and tumor vaccines [4–6]. However, the outcomes of current clinical trials regarding immune rechallenge were less than satisfactory. The reason was most likely that they ignored the important role played by the regulation of the tumor immune microenvironment (TME) in anti-tumor treatment.

β-glucan, the main component of microbial cell walls, is a linear polysaccharide linked by β-glucoside bond of D-glucose monomeris [7]. As an immune adjuvant, β-glucan has been used in clinical practice alongside other anti-tumor medications for tumor treatment [8]. Following oral administration of β-glucan, there was an increase in dendritic cells (DCs) within the TME of wild-type mice with colitis-associated colorectal cancer (CAC), resulting in enhanced production of CD8+T cells and related cytokines, ultimately leading to a delay in CAC development [9]. β-glucan could also enhance the efficacy of immunotherapy by regulating the composition of intestinal microbiota and adjusting the intestinal microenvironment [10]. Furthermore, for patients with advanced tumors resistant to anti-PD-1 inhibitors, 69.2% obtained stable disease (SD) when added with β-glucan on the basis of maintaining the original treatmennt regimen in our previous study, suggesting that β-glucan had the potential to reverse immune resistance [11].

Envafolimab is a single domain anti-PD-L1 inhibitor administered subcutaneously, which can block the PD-1/PD-L1 pathway, reactivate the suppressed T cells to induce anti-tumor immune response and recover the antigen presentation function of DCs [12–14]. Envafolimab monotherapy has been proved the anti-tumor activity and safety in the second and above line treatment for a variety of MSI-H/dMMR advanced solid tumors in phase II clinical studies [15, 16]. Nowadays, the conversion of anti-PD-1 /PD-L1 antibodies as immune rechallenge is also a treatment option for some patients with NSCLC [17, 18].

Anti-angiogenic drugs play a very important role in the treatment of advanced NSCLC, especially in lung adenocarcinoma [19]. Previous studies have shown that the abnormal blood vessels in the TME were associated with drug resistance [20]. As a novel recombinant human endostatin, Endostar can strongly inhibit VEGF expression and angiogenesis while also inducing vascular normalization [21]. By inducing vascular normalization of tumor blood vessels, it can promote the infiltration of T cells into the tumor, thereby transforming the tumor microenvironment into "hot tumor". The combination of anti-PD-1 inhibitors and Endostar exhibited a significant synergistic effect in suppressing tumor growth in preclinical lung tumor models as well as NSCLC patients [22–24].

Totally, our study aims to evaluate the efficacy and safety of β-glucan combined with Envafolimab (an anti-PD-L1 antibody) and Endostar (an angiogenesis inhibitor) in the treatment of metastatic NSCLC patients who have previously failed anti-PD-1 therapy, while also investigating potential biomarkers associated with treatment response and resistance.

Materials and methods

Study design and ethics

This is a single-arm, Phase II clincal trial (ChiCTR2100054796, Registration Date: 2021–12-27) performed at the Affiliated Changzhou No.2 People’s Hospital of Nanjing Medical University, Changzhou city, to evaluate the efficacy and safety of β-glucan combined with Envafolimab and Endostar in mNSCLC patients failed of anti-PD-1 therapy previously. Participants received β-glucan (500 mg, bid, d1-21), Envafolimab (300 mg, d1) and Endostar (210 mg, civ72h) every 3 weeks until disease progression or unacceptable toxicity. Tumor imaging and objective response assessment were performed every 2 cycles according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Patients were followed up for safety 30 days after the last cycle and followed for survival every 12 weeks after disease progression or the last cycle. The study was approved by the Ethics Committee of Changzhou No.2 People’s Hospital (Approval number: [2021YLJSD002]) and conducted in accordance with the principles of the Declaration of Helsinki. All registered patients have signed informed consent forms to participate.

Inclusion and exclusion criteria for participants

All enrolled patients were in line with the following conditions: (1) aged from 18 to 80 years old; (2) confirmed as stage IV NSCLC histologically or cytologically; (3) Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1; (4) with at least one measurable target lesion; (5) failed of anti-PD-1 therapy and never treated with PD-L1 inhibitors; (6) with sufficient organ and bone marrow function; (7) with an expected survival of at least 3 months or the ability to tolerate a minimum of 2 treatment cycles.

Patients with any of the following conditions were excluded: (1) participating in other clinical studies; (2) with invasion of large blood vessels confirmed by imaging; (3) with symptoms of central nervous system metastases; (4) with grade III-IV (New York Heart Association classification) congestive heart failure; (5) allergic to the drugs used in this trial; (6) requiring long-term systemic application of corticosteroids.

Characteristics of all enrolled patients were collected at baseline, including age, sex, pathology, driver gene mutation, ECOG PS score, number of treatment lines and expression of PD-L1. Clinical data were collected from patients receiving treatment until disease progression or death. Enrolled patients provided serum samples at baseline, when achieved best response and after disease progression. The samples were centrifuged at 2000 rpm for 10 min and stored at -80 °C for proteomic analysis.

Clinical outcomes

The primary endpoints were objective response rate (ORR) and safety. The secondary endpoints included disease control rate (DCR), progression-free survival (PFS) and overall survival (OS). The best response (BOR) is evaluated by RECIST version 1.1, classified as complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). ORR is defined as the percentage of all patients who achieved CR and PR. DCR is defined as the percentage of all patients who achieved CR, PR and SD. The NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 was used to evaluate the rating of adverse events. SPSS 25.0 and Graphpad Prism 9.0.0 were used for statistical analysis and image drawing of the data. Chi-square test, Fisher’s exact test and rank sum test were used to compare the differences in efficacy and survival outcomes between subgroups. Kaplan–Meier curves were drawn. The log-rank test was used to for the significance of survival curves in subgroups. p < 0.05 indicated that the difference was statistically significant. The safety-related results were summarized by descriptive statistics.

Proteomic analysis

Each protein was quantified by using multiple proximity extension assays. A double-recognition immunoassay mechanism was applied in which two pairs of antibodies (each with a unique DNA oligonucleotide marker) simultaneously bind to a target protein in a liquid medium, bringing the two antibodies in close proximity, allowing hybridization and serving as a template for DNA polymerase-dependent extension steps. Double-stranded DNA was unique to a particular antigen and was amplified using primers in quantities proportional to the sample concentration of the target protein. The target of amplification was quantified by RT-PCR. Protein abundance was reported as normalized protein expression (NPX), which was on the Log2 scale. In order to convert several correlated proteins into a number of uncorrelated variables and visualize the dataset, PCA for K-means clustering was performed. Double-tailed Welcht-test was performed to identify proteins which were significantly enriched or consumed in serum samples. The immune cytokines of different response groups were compared by Mann–Whitney U test and evaluated by log-rank test. R statistical program (version 3.6.3) was used for data analysis. Graphpad Prism 9.0.0 was used for further data visualization. p < 0.05 was considered statistically significant.

Results

Clinical baseline characteristics of patients

From January 2022 to March 2023, 23 patients were enrolled in this study with median age of 65 years. Among the recruited patients, 18 (78.3%) were male, 14 (60.9%) patients were adenocarcinoma, 5 (21.7%) were with ECOG PS 0. PD-L1 expression was found to be positive in 15 (65.2%) patients. Patients received β-glucan combined with Envafolimab and Endostar as 2 (10/23, 43.5%), 3 (6/23, 26.1%) or > 3 (7/23, 30.4%) lines of therapy (Table 1). Table 1 Baseline clinical characteristics of patients

Characteristics	n = 23	
Age, median (range)	65 (55, 80)	
Gender, n (%)	
 Male	18 (78.3)	
 Female	5 (21.7)	
Histopathology, n (%)	
 Adenocarcinoma	14 (60.9)	
 Squamous cell carcinoma	9 (39.1)	
Gene mutation status, n (%)	
 Mutant-type	13 (56.5)	
 Wild-type	10 (43.5)	
ECOG PS, n (%)	
 0	5 (21.7)	
 1	18 (78.3)	
Lines of therapy, n (%)	
 2	10 (43.5)	
 3	6 (26.1)	
 > 3	7 (30.4)	
PD-L1 expression, n (%)	
 Positive	15 (65.2)	
 Negative	8 (34.8)	
ECOG PS Eastern Cooperative Oncology Group performance status, PD-L1 Programmed cell death ligand-1

Efficacy evaluation

As of the data cutoff date (April 1, 2024), 5 patients achieved PR, 12 patients achieved SD and 6 patients were evaluated as PD (Fig. 1). No patients achieved CR. The overall ORR was 21.7% and DCR was 73.9% (Table 2). The median PFS was 4.3 months [95% CI: 2.0–6.6] (Fig. 2A) and the median OS was 9.8 months [95% CI: 7.2–12.4] (Fig. 2D).Fig. 1 Waterfall plot of all patients (n = 23). As of the data cutoff date (April 1, 2024), 5 patients achieved PR, 12 achieved SD and 6 patients were evaluated as PD. PR, partial response; SD, stable disease; PD, progressive disease

Table 2 Best response of all patients and subgroups

Response	All patients
(n = 23)	LUAD
(n = 14)	LUSC
(n = 9)	χ2
value	P
value	PD-L1 positive
(n = 15)	PD-L1 negative
(n = 8)	χ2
value	P
value	
BOR, n (%)	
 CR	0	0	0			0	0			
 PR	5 (21.7)	5 (35.7)	0			4 (26.7)	1 (12.5)			
 SD	12 (52.2)	7 (50.0)	5 (55.6)			9 (60.0)	3 (37.5)			
 PD	6 (26.1)	2 (21.3)	4 (44.4)			2 (13.3)	4 (50.0)			
ORR (%)	21.7	35.7	0	-	0.116	26.7	12.5	-	0.621	
DCR (%)	73.9	85.7	55.6	-	0.162	86.7	50.0	-	0.131	
BOR Best overall response, CR Complete response, PR Partial response, SD Stable disease, PD Progression of disease, ORR Objective response rate, DCR Disease control rate, PD-L1 Programmed cell death-ligand 1, LUAD Lung adenocarcinoma, LUSC Lung squamous cell carcinoma

Fig. 2 Kaplan–Meier curves of progression-free survival (PFS) and overall survival (OS). A PFS of all patients (n = 23). B PFS of LUAD (n = 14) and LUSC (n = 9) subgroups. C PFS of PD-L1 positive (n = 15) and PD-L1negative (n = 8) subgroups. D OS of all patients (n = 23). E OS of LUAD (n = 14) and LUSC (n = 9) subgroups. F OS of PD-L1 positive (n = 15) and PD-L1 negative (n = 8) subgroups. Use log-rank test to compare survival curves of subgroups. p < 0.05 is considered to be statistically significant. LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PD-L1, programmed cell death ligand-1

According to pathology and expression of PD-L1, 23 patients were categorized into different subgroups for analysis. The results showed that the ORR of patients in adenocarcinoma group and squamous cell carcinoma group were 35.7% and 0% (p = 0.116). The DCR of adenocarcinoma group was significantly higher than that of squamous cell carcinoma group (85.7% vs. 55.6%, p = 0.162). Additionally, the ORR of PD-L1 positive and negative groups were 26.7% and 12.5% (p = 0.621) and the DCR were 86.7% and 50.0%, respectively (p = 0.131) (Table 2).

Patients with adenocarcinoma tended to have better mPFS compared to those with squamous cell carcinoma, but the difference was not statistically significant (5.8 months [95% CI: 2.9–7.7] vs. 3.0 months [95% CI: 0.4–5.6], p = 0.223) (Fig. 2B). However, there was no significant difference in mOS between the two subgroups (8.2 months [95% CI: 7.0–9.0] vs. 12.3 months [95% CI: 1.6–23.0], p = 0.724) (Fig. 2E). Apart from this, the mPFS was significantly improved in PD-L1 positive patients than PD-L1 negative patients (6.3 months [95% CI: 4.7–7.9] vs. 2.3 months [95% CI: 0.3–2.9], p = 0.002) (Fig. 2C). The mOS had the same trend (9.9 months [95% CI: 3.8–16.0] vs. 8.1 months [95% CI: 5.0–10.6], p = 0.398) (Fig. 2F) between the two subgroups, though the difference was not statistically significant.

Safety

In safety analysis, 12/23 (52.2%) patients experienced treatment-related adverse events (TRAEs) during treatment. The most common TRAEs were hypothyroidism (26.1%) and fatigue (26.1%), followed with anemia (13.0%), rash (13.0%) and fever (9.7%). 2/23 (8.7%) grade 3 adverse events were reported. Up to April 2024, no immune-associated pneumonia or adverse reaction related deaths have been observed (Table 3). Table 3 Profiles of adverse events

TRAEs, n (%)	Grade	
1	2	3	4	
Fatigue	4 (17.4)	1 (4.3)	1 (4.3)	0	
Hypothyroidism	6 (26.1)	0	0	0	
Rash	3 (13.0)	0	0	0	
Anemia	1 (4.3)	1 (4.3)	1 (4.3)	0	
Fever	2 (8.7)	0	0	0	
TRAE Treatment-related adverse events

Protemic expression and analysis

Serum samples were collected at baseline, when achieved response and/or disease progression. Proteomic tests were performed on serum samples of 9 patients ultimately (Fig. 3A, B). A total of 5 cytokines were found to be significantly different before and after tumor progression, including CASP-8, ARG1, MMP12, CD28 and CXCL5 (Fig. 3C, D, Figure S2A).Fig. 3 Data preprocessing for DEGs and protemic analysis results of 9 patients. A A Boxplot of data preprocessing for different expressed proteins (DEPs). B Heat map of DEPs in all patients (n = 9). Red or blue represents high or low expression. C Volcano plot of DEPs before and after progression in all patients (n = 9). Red dots represent significantly associated proteins at FDR ≤ 5%. D Boxplot of significantly different DEPs in plasma of all patients (n = 9) before and after progression. E Volcano plot of DEPs of RG (n = 6) and NRG (n = 3) at baseline. Red dots represent significantly associated proteins at FDR ≤ 5%. F Boxplot of significantly different DEPs in RG and NRG at baseline. G Volcano plot of DEPs in RG (n = 6) before and after response. Red dots represent significantly associated proteins at FDR ≤ 5%. H Boxplot of significantly different DEPs in plasma of RG before and after response. The DEPs were compared by Mann–Whitney U test and evaluated by Log-rank test. *p < 0.05, **p < 0.01. RG, response group. NRG, non-response group. DEPs, different expressed proteins. NPX, normalized protein expression

Nine patients were divided into a response group (n = 6, PR + SD) and a non-response group (n = 3, PD) according to the best response. The results showed that IL-6, CD83 and ICOSLG had significant differences at baseline between response group and non-response group (Fig. 3E, F, Figure S1A, Figure S2B).

In response group, 2 patients achieved PR and 4 patients achieved SD. We then compared the cytokines of patients in response group at baseline and after response to the treatment and found that the levels of CD40-L and EGF relate to the favorable response (Fig. 3G, H, Figure S1B, Figure S2C). Univariate and multivariate cox regression analysis was used to explore the correlation between cytokines with PFS or OS at baseline in the two groups, but the results showed no significant differences.

Discussion

Recently, there has been a growing body of research dedicated to the investigation of immune rechallenge [25]. For NSCLC, several studies with small samples of immune rechallenge were reported while the efficacy varied widely. The ORR ranged from 5.9% to 14.3%, and DCR ranged from 45.8% to 85.7% for single immunotherapy [17, 18, 26]. Dual immunotherapy achieved an ORR of 47.3% and a DCR of up to 81.5% [27]. A comprehensive meta-analysis encompassing 49 studies was conducted to access the efficacy and safety of immune rechallenge in patients with solid tumors. The findings revealed an ORR rate of 21.8%, a mPFS of 4.9 months and a mOS of 15.6 months while the incidence of adverse events was 52.2%, including 21.5% for grade 3 and above [28]. For our study, the ORR rate, mPFS was 21.7%, 4.3 months, which is similar to the above study. However, the mOS was 9.8 months, which is significantly lower than the above study. This may be attributed to the preponderance of patients with 3 lines or above in our study. Meanwhile, the incidence of adverse events in our study was 52.2%, with no grade 4 adverse events or new specific immune-related adverse events occurred, indicating that this treatment regimen (β-glucan combined with Envafolimab and Endostar) is feasible and safe as immune rechallenge for mNSCLC patients.

Modulating TME from an immunosuppressive environment to an inflammatory environment holds great promise for achieving immune rechallenge [29]. In this process, β-glucan offers a new treatment perspective. Previous studies have demonstrated that β-glucan can activate DCs and macrophages, inhibit MDSCs and TEDCs, thereby eliminating tumor-induced immunosuppression [30, 31]. It also regulates nature killer (NK) cell function by altering macrophage phenotype, enhancing antigen presentation, promoting initiation and differentiation of cytotoxic T lymphocytes [32–35]. The addition of β-glucan is of great value in improving the immunosuppressive TME, especially in combination with ICIs. For example, Hu et al. discovered that β-glucan can enhance the antitumor effects of anti-PD-L1 inhibitors in melanoma models [36]. Wang et al. developed an antibody-β-glucan conjugate (AGC) by linking β-glucan with anti-PD-L1 inhibitors, the AGC-mediated bridging effect enhanced the interaction between tumor cells and DCs. Compared to anti-PD-L1 inhibitors monotherapy, AGC induced the infiltration of DCs and the activation of T cells in TME, resulting in an earlier immune response [37].

Anti-PD-1 inhibitors and anti-PD-L1 inhibitors have been regarded as the same drug for a long time. Typically, anti-PD-L1 inhibitors are usually not applied after resistance to anti-PD-1 inhibitors. As research progresses, many studies indicated mechanistic differences between anti-PD-L1 and anti-PD-1 inhibitors. In addition to inhibiting the PD-1/PD-L1 pathway, anti-PD-L1 inhibitors can also inhibit the overexpression of PD-L1 on the surface of DCs in the TME, thus activating the antigen presentation function of DCs and recruiting T cells for the unique killing of tumor cells [38–40]. In the past few years, many studies found that after the progress of anti-PD-1 treatment, the usage of anti-PD-L1 antibody could also obtain a fairly controllable therapeutic efficacy [41–43]. Therefore, conversion of anti-PD-1/PD-L1 antibody is also an emerging therapeutic regimen as immune rechallenge strategy.

In the subgroup analysis, there were no significant differences observed in ORR between adenocarcinoma and squamous cell carcinoma subgroups or between PD-L1 positive and negative subgroups. Patients with adenocarcinoma tended to have better mPFS compared to those with squamous cell carcinoma, but the difference was not statistically significant. This may be attributed to the limited sample size. At the same time, there was no difference in mOS. It is important to note that PFS reflects short-term treatment effects, whereas OS can be influenced by various factors such as ECOG PS status, site of metastasis, lines of treatment, etc. Therefore, it was not uncommon to see differences in PFS but often no differences in OS in clinical studies. The high expression of PD-L1 at baseline has been associated with enhanced efficacy of anti-PD-1/PD-L1 therapy in advanced NSCLC [44, 45]. However, it is not clear whether PD-L1 levels change during the previous immunotherapy. At present, the redetection of PD-L1 expression before immune rechallenge is still rare. Whether PD-L1 can be used as a therapeutic marker for immune rechallenge is controversial [46, 47]. In our study, the PFS of PD-L1 positive subgroup was significantly better than that of PD-L1 negative subgroup. The OS data showed the same trend with no significant difference, which we thought was also related to the small sample size. These results indicated that the expression of PD-L1 at baseline might also serve as a prognostic biomarker for immune rechallenge.

Admittedly, effective biomarkers for immune rechallenge are currently lacking. Therefore, we collected peripheral blood samples from patients at different treatment time points and conducted proteomic analysis in an attempt to identify potential markers for therapeutic efficacy and prognosis. A total of 5 cytokines, including CASP-8, ARG1, MMP12, CD28 and CXCL5, were found to be significantly different before and after tumor progression and we considered this might be related to the treatment resistance. Among the cytokines, previous studies have shown that MMP12 and ARG1 were associated with poor prognosis in various tumors [48, 49] and CASP-8 promoted melanoma progression [50]. The increase of CD8+CD28+ T cells in advanced NSCLC patients who received chemo (radio) therapy predicted treatment efficacy and prognosis [51, 52]. However, the results of CXCL5 in our study could not be confirmed by current studies, as CXCL5 tended to be associated with poor prognosis in many solid tumors [53].

Comparing between response and non-response groups, mNSCLC patients with lower ICOSLG and CD83 at baseline responded better to the treatment, but the specific thresholds remains unknown [54, 55]. However, high expression of IL-6 associated with poor efficacy with immunosuppression in many tumors [56], which differed from our results. Furthermore, CD40-L can activate NK cells, CD4+ and CD8+ T cells and inhibit tumor progression [57]. EGF signaling is the core in regulating tumor cell proliferation [58]. The levels of CD40-L and EGF might relate to the favorable response. However, due to the limited number of patients enrolled in proteomic analysis, the results should be interpreted with caution. Further investigation is required in a larger cohort to validate these proteins’ association with resistance or response to immune rechallenge, thus providing more reliable predictive biomarkers for guiding clinical work.

The main limitation of this study was that the patients enrolled in the study were not enough, leading to insufficient statistical power in the analysis. Enrollment should be expanded or a multi-center clinical study could be conducted in the follow-up studies. Secondly, as a single-arm study, it was difficult to accurately compare the efficacy and side effects with other treatment regimens in immune rechallenge studies. Despite these limitations, this study was the first attempt to demonstrate that β-glucan combined with Envafolimab and Endostar has considerable efficacy in patients who have failed previous anti-PD-1 treatment. As a “chemo-free” treatment regimen, attempting to regulate the TME for the purpose of immune rechallenge, this is more acceptable for cancer patients.

Conclusion

In summary, β-glucan combined with Envafolimab and Endostar has considerable efficacy and safety for immune rechallenge in metastatic NSCLC patients who failed of anti-PD-1 treatment previously. Especially, PD-L1 positive patients can benefit more from immune rechallenge than PD-L1 negative patients.

Supplementary Information

Supplementary Material 1: Supplemental Figure 1. Heat maps of different groups. (A) Heat map of DEPs in RG (n=6) and NRG (n=3) at baseline. Red or blue represents high or low expression. (B) Heat map of DEPs in RG (n=6) before and after response. Red or blue represents high or low expression. DEPs, different expressed proteins. RG, response group. NRG, non-response group.

Supplementary Material 2: Supplemental Figure 2. PCA results of different groups. (A) PCA of 9 patients before and after response. (B) PCA of RG (n=6) and NRG (n=3) at baseline. (C) PCA of RG (n=6) before and after response. PCA shows no significant differences. PCA, principal components analysis. RG, response group. NRG, non-response group.

Abbreviations

AGC Antibody-β-glucan conjugate

BOR Best overall response

CAC Colitis associated colorectal cancer

CR Complete response

CTCAE Common Terminology Criteria for Adverse Events

DC Dendritic cell

DCR Disease control rate

DEP Different expressed proteins

ECOG PS Eastern Cooperative Oncology Group performance status

ICI Immune checkpoint inhibitor

irAE Immune-related Adverse Event

LUAD Lung adenocarcinoma

LUSC Lung squamous cell carcinoma

MDSC Myeloid-derived suppressor cell

mNSCLC Metastatic non-small cell lung cancer

mPFS Median progression-free survival

mOS Median overall survival

NK Natural killer

NPX Normalized protein expression

NRG Non-response group

NSCLC Non-small-cell lung cancer

ORR Objective response rate

OS Overall survival

PCA Principal components analysis

PD Progression of disease

PD-1 Programmed cell death-1

PD-L1 Programmed cell death ligand-1

PFS Progression-free survival

PR Partial response

RECIST Response Evaluation Criteria in Solid Tumors

RG Response group

SD Stable disease

TEDC Tumor-educated dendritic cell

TME Tumor microenvironment

TRAE Treatment-related adverse events

Acknowledgements

We would like to thank the patients and family members who gave their consent to present the data in this study, as well as the investigators involved in this study.

Authors’ contributions

QG, HJ, DL and CQ, conceptualization. XP, YZ, YZ, QZ, and GW, investigation. YL, LQ, original draft writing and formal analysis. QG, HJ, DL, review and editing. All authors contributed to the article and approved the submitted version.

Funding

This study was supported by the 2022 Clinical Research project of Changzhou Medical Center, Nanjing Medical University (CMCC202201), the 2021 Science and Technology Project of Changzhou Health Commission (Major Science and Technology Project) (ZD202113), 2021 Science and Technology Project of Changzhou Health Commission (Young Talent Science and Technology Project) (QN202116), 2022 Changzhou 8th Batch of Science and Technology Project (Applied Basic Research) (CJ20220086). The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or decision to submit the manuscript for publication.

Availability of data and materials

The datasets generated and analyzed during the current study are not publicly available due to limitations of ethical approval involving the patient data but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study was approved by the Ethics Committee of Changzhou No.2 People’s Hospital (Approval number: [2021YLJSD002]) and conducted in accordance with the principles of the Declaration of Helsinki. All registered patients have signed informed consent forms to participate.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Qian Geng and Yingying Lu joint first author.
==== Refs
References

1. Siegel RL Miller KD Wagle NS Jemal A Cancer statistics, 2023 CA Cancer J Clin. 2023 73 17 48 10.3322/caac.21763 36633525
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.36633525 10.3322/caac.21763
2. Lahiri A Maji A Potdar PD Singh N Parikh P Bisht B Lung cancer immunotherapy: progress, pitfalls, and promises Mol Cancer 2023 22 40 10.1186/s12943-023-01740-y 36810079
Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22:40.36810079 10.1186/s12943-023-01740-y
3. Schoenfeld AJ Hellmann MD Acquired Resistance to Immune Checkpoint Inhibitors Cancer Cell 2020 37 443 455 10.1016/j.ccell.2020.03.017 32289269
Schoenfeld AJ, Hellmann MD. Acquired Resistance to Immune Checkpoint Inhibitors. Cancer Cell. 2020;37:443–55.32289269 10.1016/j.ccell.2020.03.017
4. Zhang H Hu Y Wu T Chen Y Yang B Xie T Clinical characteristics and novel strategies of immune checkpoint inhibitor rechallenge therapy for non-small cell lung cancer: a comprehensive review Front Immunol 2023 14 1309055 10.3389/fimmu.2023.1309055 38283354
Zhang H, Hu Y, Wu T, Chen Y, Yang B, Xie T. Clinical characteristics and novel strategies of immune checkpoint inhibitor rechallenge therapy for non-small cell lung cancer: a comprehensive review. Front Immunol. 2023;14:1309055.38283354 10.3389/fimmu.2023.1309055
5. Livanou ME Nikolaidou V Skouras V Fiste O Kotteas E Efficacy of NSCLC Rechallenge with Immune Checkpoint Inhibitors following Disease Progression or Relapse Cancers 2024 16 1196 10.3390/cancers16061196 38539530
Livanou ME, Nikolaidou V, Skouras V, Fiste O, Kotteas E. Efficacy of NSCLC Rechallenge with Immune Checkpoint Inhibitors following Disease Progression or Relapse. Cancers. 2024;16:1196.38539530 10.3390/cancers16061196
6. Desai A Peters S Immunotherapy-based combinations in metastatic NSCLC Cancer Treat Rev 2023 116 102545 10.1016/j.ctrv.2023.102545 37030062
Desai A, Peters S. Immunotherapy-based combinations in metastatic NSCLC. Cancer Treat Rev. 2023;116: 102545.37030062 10.1016/j.ctrv.2023.102545
7. De Marco CE Calder PC Roche HM β-1,3/1,6-Glucans and Immunity: State of the Art and Future Directions Mol Nutr Food Res 2021 65 1901071 10.1002/mnfr.201901071 32223047
De Marco CE, Calder PC, Roche HM. β-1,3/1,6-Glucans and Immunity: State of the Art and Future Directions. Mol Nutr Food Res. 2021;65:1901071.32223047 10.1002/mnfr.201901071
8. Jin Y Li P Wang F β-glucans as potential immunoadjuvants: A review on the adjuvanticity, structure-activity relationship and receptor recognition properties Vaccine 2018 36 5235 5244 10.1016/j.vaccine.2018.07.038 30049632
Jin Y, Li P, Wang F. β-glucans as potential immunoadjuvants: A review on the adjuvanticity, structure-activity relationship and receptor recognition properties. Vaccine. 2018;36:5235–44.30049632 10.1016/j.vaccine.2018.07.038
9. Xie Y Shao F Duan X Ding J Ning Y Sun X Whole β-glucan particle attenuates AOM/DSS-induced colorectal tumorigenesis in mice via inhibition of intestinal inflammation Front Pharmacol 2023 14 1017475 10.3389/fphar.2023.1017475 36713833
Xie Y, Shao F, Duan X, Ding J, Ning Y, Sun X, et al. Whole β-glucan particle attenuates AOM/DSS-induced colorectal tumorigenesis in mice via inhibition of intestinal inflammation. Front Pharmacol. 2023;14:1017475.36713833 10.3389/fphar.2023.1017475
10. Muthukumaran J Jiali C Stephen C Baojun X A critical review on the impacts of β-glucans on gut microbiota and human health J Nutr Biochem 2018 61 101 110 10.1016/j.jnutbio.2018.06.010 30196242
Muthukumaran J, Jiali C, Stephen C, Baojun X. A critical review on the impacts of β-glucans on gut microbiota and human health. J Nutr Biochem. 2018;61:101–10.30196242 10.1016/j.jnutbio.2018.06.010
11. Wang M Bai Y Pei J Li D Pu X Zhu W β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer Front Pharmacol 2022 13 887457 10.3389/fphar.2022.887457 35548349
Wang M, Bai Y, Pei J, Li D, Pu X, Zhu W, et al. β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer. Front Pharmacol. 2022;13: 887457.35548349 10.3389/fphar.2022.887457
12. Zhang F Wei H Wang X Bai Y Wang P Wu J Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade Cell Discovery 2017 3 17004 10.1038/celldisc.2017.4 28280600
Zhang F, Wei H, Wang X, Bai Y, Wang P, Wu J, et al. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discovery. 2017;3:17004.28280600 10.1038/celldisc.2017.4
13. Envafolimab MA First Approval Drugs 2022 82 235 240 10.1007/s40265-022-01671-w 35122636
Envafolimab MA. First Approval. Drugs. 2022;82:235–40.35122636 10.1007/s40265-022-01671-w
14. Mayoux M Roller A Pulko V Sammicheli S Chen S Sum E Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy Science Translational Medicine 2020 12 7431 10.1126/scitranslmed.aav7431
Mayoux M, Roller A, Pulko V, Sammicheli S, Chen S, Sum E, et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Science Translational Medicine. 2020;12:7431.10.1126/scitranslmed.aav7431
15. Papadopoulos KP Harb W Peer CJ Hua Q Xu S Lu H First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors Oncologist 2021 26 1514 1525 10.1002/onco.13817
Papadopoulos KP, Harb W, Peer CJ, Hua Q, Xu S, Lu H, et al. First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors. Oncologist. 2021;26:1514–25.10.1002/onco.13817
16. Li J Deng Y Zhang W Zhou AP Guo W Yang J Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors J Hematol Oncol 2021 14 95 10.1186/s13045-021-01095-1 34154614
Li J, Deng Y, Zhang W, Zhou AP, Guo W, Yang J, et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors. J Hematol Oncol. 2021;14:95.34154614 10.1186/s13045-021-01095-1
17. Shingo K Taiki H Rui K Yukio H Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review Thoracic Cancer 2020 11 1927 1933 10.1111/1759-7714.13483 32421224
Shingo K, Taiki H, Rui K, Yukio H. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review. Thoracic Cancer. 2020;11:1927–33.32421224 10.1111/1759-7714.13483
18. Yutaka T Takuya T Yoko I Ikuyo S Kouichi Y Takashi S Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non-small cell lung cancer Thoracic Cancer 2022 13 624 630 10.1111/1759-7714.14309 34989146
Yutaka T, Takuya T, Yoko I, Ikuyo S, Kouichi Y, Takashi S, et al. Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non-small cell lung cancer. Thoracic Cancer. 2022;13:624–30.34989146 10.1111/1759-7714.14309
19. Martin R Sanjay P Christian G Jesus C Silvia N Maya G Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives Lung Cancer 2023 179 107173 10.1016/j.lungcan.2023.03.009 36940614
Martin R, Sanjay P, Christian G, Jesus C, Silvia N, Maya G, et al. Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives. Lung Cancer. 2023;179: 107173.36940614 10.1016/j.lungcan.2023.03.009
20. Elizabeth K Melissa Y Avinoam B Christina L Henriett B Shan M Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma J Natl Cancer Inst 2016 108 030
Elizabeth K, Melissa Y, Avinoam B, Christina L, Henriett B, Shan M, et al. Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma. J Natl Cancer Inst. 2016;108:030.
21. Yi M Jiao D Qin S Chu Q Wu K Li A Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment Mol Cancer 2019 18 60 10.1186/s12943-019-0974-6 30925919
Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18:60.30925919 10.1186/s12943-019-0974-6
22. Wu J Zhao XG Sun QF Jiang YF Zhang WQ Luo JW Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model Biomed Pharmacother 2020 125 109746 10.1016/j.biopha.2019.109746 32106386
Wu J, Zhao XG, Sun QF, Jiang YF, Zhang WQ, Luo JW, et al. Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model. Biomed Pharmacother. 2020;125:109746.32106386 10.1016/j.biopha.2019.109746
23. Jiang X EP11.02–10 Efficacy and Safety of Combining Envafolimab with Endostar in Advanced NSCLC: A Multi-Center Prospective Study (Endouble) J Thorac Oncol 2023 18 Suppl 618 619 10.1016/j.jtho.2023.09.1172
Jiang X. EP11.02–10 Efficacy and Safety of Combining Envafolimab with Endostar in Advanced NSCLC: A Multi-Center Prospective Study (Endouble). J Thorac Oncol. 2023;18 Suppl:618–9.10.1016/j.jtho.2023.09.1172
24. Yuan S Miao C 70P Phase II clinical study of envafolimab combined with recombinant human endostatin and chemotherapy as a first-line treatment for driver gene-negative advanced non-small cell lung cancer ESMO Open 2024 9 Suppl 3 102649 10.1016/j.esmoop.2024.102649
Yuan S, Miao C. 70P Phase II clinical study of envafolimab combined with recombinant human endostatin and chemotherapy as a first-line treatment for driver gene-negative advanced non-small cell lung cancer. ESMO Open. 2024;9(Suppl 3): 102649.10.1016/j.esmoop.2024.102649
25. Han H Ke W Rong J Zixun Z Min Z Yuanle D Current Status in Rechallenge of Immunotherapy Int J Biol Sci 2023 19 2428 2442 10.7150/ijbs.82776 37215995
Han H, Ke W, Rong J, Zixun Z, Min Z, Yuanle D, et al. Current Status in Rechallenge of Immunotherapy. Int J Biol Sci. 2023;19:2428–42.37215995 10.7150/ijbs.82776
26. Atsuto M Kyoichi K Ou Y Ayako S Yu M Kosuke H Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer Cancer Chemother Pharmacol 2019 84 873 880 10.1007/s00280-019-03926-y 31444618
Atsuto M, Kyoichi K, Ou Y, Ayako S, Yu M, Kosuke H, et al. Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer. Cancer Chemother Pharmacol. 2019;84:873–80.31444618 10.1007/s00280-019-03926-y
27. Fernando S Hira R Andrew P Andy N Mario L Maya G Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC Cancer Immunol Res 2018 6 1093 1099 10.1158/2326-6066.CIR-17-0755 29991499
Fernando S, Hira R, Andrew P, Andy N, Mario L, Maya G, et al. Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. Cancer Immunol Res. 2018;6:1093–9.29991499 10.1158/2326-6066.CIR-17-0755
28. Inno A Roviello G Ghidini A Luciani A Catalano M Gori S Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis Crit Rev Oncol Hematol 2021 165 103434 10.1016/j.critrevonc.2021.103434 34343657
Inno A, Roviello G, Ghidini A, Luciani A, Catalano M, Gori S, et al. Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;165: 103434.34343657 10.1016/j.critrevonc.2021.103434
29. Zhang M Kim JA Huang AY Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles Front Immunol 2018 9 341 10.3389/fimmu.2018.00341 29535722
Zhang M, Kim JA, Huang AY. Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles. Front Immunol. 2018;9:341.29535722 10.3389/fimmu.2018.00341
30. Tian J Ma J Ma K Guo H Baidoo SE Zhang Y β-Glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid-derived suppressor cells Eur J Immunol 2013 43 1220 1230 10.1002/eji.201242841 23424024
Tian J, Ma J, Ma K, Guo H, Baidoo SE, Zhang Y, et al. β-Glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid-derived suppressor cells. Eur J Immunol. 2013;43:1220–30.23424024 10.1002/eji.201242841
31. Ning Y Xu D Zhang X Bai Y Ding J Feng T β-glucan restores tumor-educated dendritic cell maturation to enhance antitumor immune responses Int J Cancer 2016 138 2713 2723 10.1002/ijc.30002 26773960
Ning Y, Xu D, Zhang X, Bai Y, Ding J, Feng T, et al. β-glucan restores tumor-educated dendritic cell maturation to enhance antitumor immune responses. Int J Cancer. 2016;138:2713–23.26773960 10.1002/ijc.30002
32. Yan J Allendorf DJ Brandley B Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer Expert Opin Biol Ther 2005 5 691 702 10.1517/14712598.5.5.691 15934844
Yan J, Allendorf DJ, Brandley B. Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer. Expert Opin Biol Ther. 2005;5:691–702.15934844 10.1517/14712598.5.5.691
33. Qi C Cai Y Gunn L Ding C Li B Kloecker G Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived β-glucans Blood 2011 117 6825 6836 10.1182/blood-2011-02-339812 21531981
Qi C, Cai Y, Gunn L, Ding C, Li B, Kloecker G, et al. Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived β-glucans. Blood. 2011;117:6825–36.21531981 10.1182/blood-2011-02-339812
34. Zhu Z He L Bai Y Xia L Sun X Qi C Yeast β-glucan modulates macrophages and improves antitumor NK-cell responses in cancer Clin Exp Immunol 2023 214 50 60 10.1093/cei/uxad080 37455659
Zhu Z, He L, Bai Y, Xia L, Sun X, Qi C. Yeast β-glucan modulates macrophages and improves antitumor NK-cell responses in cancer. Clin Exp Immunol. 2023;214:50–60.37455659 10.1093/cei/uxad080
35. Ding J Ning Y Bai Y Xu X Sun X Qi C β-Glucan induces autophagy in dendritic cells and influences T-cell differentiation Med Microbiol Immunol 2019 208 39 48 10.1007/s00430-018-0556-z 30088084
Ding J, Ning Y, Bai Y, Xu X, Sun X, Qi C. β-Glucan induces autophagy in dendritic cells and influences T-cell differentiation. Med Microbiol Immunol. 2019;208:39–48.30088084 10.1007/s00430-018-0556-z
36. Hu X Shui Y Hirano H Kusano K Guo WZ Fujino M PD-L1 antibody enhanced β-glucan antitumor effects via blockade of the immune checkpoints in a melanoma model Cancer Immunology, Immunotherapy: CII 2023 72 719 731 10.1007/s00262-022-03276-4 36053290
Hu X, Shui Y, Hirano H, Kusano K, Guo WZ, Fujino M, et al. PD-L1 antibody enhanced β-glucan antitumor effects via blockade of the immune checkpoints in a melanoma model. Cancer Immunology, Immunotherapy: CII. 2023;72:719–31.36053290 10.1007/s00262-022-03276-4
37. Wang Q Jiang H Zhang H Lu W Wang X Xu W β-Glucan-conjugated anti-PD-L1 antibody enhances antitumor efficacy in preclinical mouse models Carbohyd Polym 2024 324 121564 10.1016/j.carbpol.2023.121564
Wang Q, Jiang H, Zhang H, Lu W, Wang X, Xu W, et al. β-Glucan-conjugated anti-PD-L1 antibody enhances antitumor efficacy in preclinical mouse models. Carbohyd Polym. 2024;324: 121564.10.1016/j.carbpol.2023.121564
38. Jiang Y Chen M Nie H Yuan Y PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations Hum Vaccin Immunother 2019 15 1111 1122 10.1080/21645515.2019.1571892 30888929
Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15:1111–22.30888929 10.1080/21645515.2019.1571892
39. Shklovskaya E Rizos H Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy Int J Mol Sci 2020 21 7139 10.3390/ijms21197139 32992658
Shklovskaya E, Rizos H. Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy. Int J Mol Sci. 2020;21:7139.32992658 10.3390/ijms21197139
40. Oh SA Wu DC Cheung J Navarro A Xiong H Cubas R PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer Nature Cancer 2020 1 681 691 10.1038/s43018-020-0075-x 35122038
Oh SA, Wu DC, Cheung J, Navarro A, Xiong H, Cubas R, et al. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nature Cancer. 2020;1:681–91.35122038 10.1038/s43018-020-0075-x
41. Fujita K Uchida N Yamamoto Y Kanai O Okamura M Nakatani K Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies Anticancer Res 2019 39 3917 3921 10.21873/anticanres.13543 31262921
Fujita K, Uchida N, Yamamoto Y, Kanai O, Okamura M, Nakatani K, et al. Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies. Anticancer Res. 2019;39:3917–21.31262921 10.21873/anticanres.13543
42. Naoki F Makoto N Kazushige W Satoshi I Takashi S Ryota U Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody Thoracic Cancer 2021 12 613 618 10.1111/1759-7714.13824 33448648
Naoki F, Makoto N, Kazushige W, Satoshi I, Takashi S, Ryota U, et al. Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody. Thoracic Cancer. 2021;12:613–8.33448648 10.1111/1759-7714.13824
43. Yaxiong Z Zihong C Yu L Liang H Wei J Qiming W Chidamide plus envafolimab as subsequent treatment in advanced non-small cell lung cancer patients resistant to anti-PD-1 therapy: A multicohort, open-label, phase II trial with biomarker analysis Cancer Med 2024 13 7175 10.1002/cam4.7175
Yaxiong Z, Zihong C, Yu L, Liang H, Wei J, Qiming W, et al. Chidamide plus envafolimab as subsequent treatment in advanced non-small cell lung cancer patients resistant to anti-PD-1 therapy: A multicohort, open-label, phase II trial with biomarker analysis. Cancer Med. 2024;13:7175.10.1002/cam4.7175
44. Sezer A Kilickap S Gümüş M Bondarenko I Özgüroğlu M Gogishvili M Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial Lancet (London, England) 2021 397 592 604 10.1016/S0140-6736(21)00228-2 33581821
Sezer A, Kilickap S, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet (London, England). 2021;397:592–604.33581821 10.1016/S0140-6736(21)00228-2
45. Li J Gu J PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis Future Oncology (London, England) 2019 15 1667 1678 10.2217/fon-2018-0639 31041879
Li J, Gu J. PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis. Future Oncology (London, England). 2019;15:1667–78.31041879 10.2217/fon-2018-0639
46. Yuki K Takayuki S Tadaaki Y Takayuki T Takahiro Y Shinsuke S Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer J Clin Med 2020 9 102
Yuki K, Takayuki S, Tadaaki Y, Takayuki T, Takahiro Y, Shinsuke S, et al. Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer. J Clin Med. 2020;9:102.
47. Kohei F Naohiro U Osamu K Misato O Koichi N Tadashi M Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases Cancer Chemother Pharmacol 2018 81 1105 1109 10.1007/s00280-018-3585-9 29675747
Kohei F, Naohiro U, Osamu K, Misato O, Koichi N, Tadashi M. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases. Cancer Chemother Pharmacol. 2018;81:1105–9.29675747 10.1007/s00280-018-3585-9
48. Ella E Harel Y Abraham M Wald H Benny O Karsch-Bluman A Matrix metalloproteinase 12 promotes tumor propagation in the lung J Thorac Cardiovasc Surg 2018 155 2164 2175 10.1016/j.jtcvs.2017.11.110 29429629
Ella E, Harel Y, Abraham M, Wald H, Benny O, Karsch-Bluman A, et al. Matrix metalloproteinase 12 promotes tumor propagation in the lung. J Thorac Cardiovasc Surg. 2018;155:2164–75.29429629 10.1016/j.jtcvs.2017.11.110
49. Zhang H Zhu X Friesen TJ Kwak JW Pisarenko T Mekvanich S Annexin A2/TLR2/MYD88 pathway induces arginase 1 expression in tumor-associated neutrophils J Clin Investig 2022 132 153643 10.1172/JCI153643
Zhang H, Zhu X, Friesen TJ, Kwak JW, Pisarenko T, Mekvanich S, et al. Annexin A2/TLR2/MYD88 pathway induces arginase 1 expression in tumor-associated neutrophils. J Clin Investig. 2022;132: 153643.10.1172/JCI153643
50. Zou J Xia H Zhang C Xu H Tang Q Zhu G Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy Cancer Sci 2021 112 2664 2678 10.1111/cas.14932 33934451
Zou J, Xia H, Zhang C, Xu H, Tang Q, Zhu G, et al. Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy. Cancer Sci. 2021;112:2664–78.33934451 10.1111/cas.14932
51. Huff WX Kwon JH Henriquez M Fetcko K Dey M The Evolving Role of CD8 + CD28- Immunosenescent T Cells in Cancer Immunology Int J Mol Sci 2019 20 2810 10.3390/ijms20112810 31181772
Huff WX, Kwon JH, Henriquez M, Fetcko K, Dey M. The Evolving Role of CD8 + CD28- Immunosenescent T Cells in Cancer Immunology. Int J Mol Sci. 2019;20:2810.31181772 10.3390/ijms20112810
52. Liu C Jing W An N Li A Yan W Zhu H Prognostic significance of peripheral CD8+CD28+ and CD8+CD28- T cells in advanced non-small cell lung cancer patients treated with chemo(radio)therapy J Transl Med 2019 17 344 10.1186/s12967-019-2097-7 31623615
Liu C, Jing W, An N, Li A, Yan W, Zhu H, et al. Prognostic significance of peripheral CD8+CD28+ and CD8+CD28- T cells in advanced non-small cell lung cancer patients treated with chemo(radio)therapy. J Transl Med. 2019;17:344.31623615 10.1186/s12967-019-2097-7
53. Zhang W Wang H Sun M Deng X Wu X Ma Y CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target Cancer Communications (London, England) 2020 40 69 80 10.1002/cac2.12010 32237072
Zhang W, Wang H, Sun M, Deng X, Wu X, Ma Y, et al. CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target. Cancer Communications (London, England). 2020;40:69–80.32237072 10.1002/cac2.12010
54. Naqash AR McCallen JD Mi E Iivanainen S Marie MA Gramenitskaya D Clark J Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer J Immunother Cancer 2023 11 007310 10.1136/jitc-2023-007310
Naqash AR, McCallen JD, Mi E, Iivanainen S, Marie MA, Gramenitskaya D, Clark J, et al. Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer. J Immunother Cancer. 2023;11: 007310.10.1136/jitc-2023-007310
55. Zhang Y Wang XL Liu JJ Qian ZY Pan ZY Song NP ICOS/ICOSLG and PD-1 Co-Expression is Associated with the Progression of Colorectal Precancerous- Carcinoma Immune Microenvironment J Inflamm Res 2023 16 977 992 10.2147/JIR.S401123 36915615
Zhang Y, Wang XL, Liu JJ, Qian ZY, Pan ZY, Song NP, et al. ICOS/ICOSLG and PD-1 Co-Expression is Associated with the Progression of Colorectal Precancerous- Carcinoma Immune Microenvironment. J Inflamm Res. 2023;16:977–92.36915615 10.2147/JIR.S401123
56. Baleeiro RB Bergami-Santos PC Tomiyoshi MY Gross JL Haddad F Pinto CA Expression of a dendritic cell maturation marker CD83 on tumor cells from lung cancer patients and several human tumor cell lines: is there a biological meaning behind it? Cancer Immunology, Immunotherapy: CII 2008 57 265 270 10.1007/s00262-007-0344-x 17628801
Baleeiro RB, Bergami-Santos PC, Tomiyoshi MY, Gross JL, Haddad F, Pinto CA, et al. Expression of a dendritic cell maturation marker CD83 on tumor cells from lung cancer patients and several human tumor cell lines: is there a biological meaning behind it? Cancer Immunology, Immunotherapy: CII. 2008;57:265–70.17628801 10.1007/s00262-007-0344-x
57. Luo P Deng S Ye H Yu X Deng Q Zhang Y The IL-33/ST2 pathway suppresses murine colon cancer growth and metastasis by upregulating CD40 L signaling Biomed Pharmacother 2020 127 110232 10.1016/j.biopha.2020.110232 32559854
Luo P, Deng S, Ye H, Yu X, Deng Q, Zhang Y, et al. The IL-33/ST2 pathway suppresses murine colon cancer growth and metastasis by upregulating CD40 L signaling. Biomed Pharmacother. 2020;127: 110232.32559854 10.1016/j.biopha.2020.110232
58. Boch T Köhler J Janning M Loges S Targeting the EGF receptor family in non-small cell lung cancer—increased complexity and future perspectives Cancer Biol Med 2022 19 1543 1564 10.20892/j.issn.2095-3941.2022.0540 36476337
Boch T, Köhler J, Janning M, Loges S. Targeting the EGF receptor family in non-small cell lung cancer—increased complexity and future perspectives. Cancer Biol Med. 2022;19:1543–64.36476337 10.20892/j.issn.2095-3941.2022.0540
